source
- Legend Biotech shares jump 40% after promising early CAR-T data in Non-Hodgkin’s lymphomaShares of Legend Biotech rose more than 40% after the company released early results from its in vivo CAR‑T therapy targeting Non‑Hodgkin’s lymphoma. The data showed encouraging activity and a mana…
- Cigna to End Coverage of GLP-1 Weight-Loss Drugs Wegovy and Zepbound for Employees Starting July 1Cigna announced it will stop covering GLP-1 weight-loss medications for its employee health plan, effective July 1. The decision affects drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepboun…